Skip to main content

Table 2 Subgroup analysis of the prognostic value of CALLY in patients with digestive system neoplasms

From: Prognostic and clinicopathological significance of C-reactive protein–albumin–lymphocyte(CALLY) in patients with digestive system neoplasms: a systematic review and meta-analysis

Subgroups

No. of studies

No. of patients

Effects mode

HR (95%CI)

p

Heterogeneity

I2 (%)

Ph

OS

       

Total

16

7335

Fixed

2.03(1.83–2.25)

P < 0.00001

0

0.76

Country

       

China

2

1944

Fixed

2.13(1.76,2.58)

P < 0.00001

0

0.44

Japan

14

5391

Fixed

1.99(1.76,2.25)

P < 0.00001

0

0.70

Sample size

       

≤ 300

6

1086

Fixed

2.17(1.73,2.72)

P < 0.00001

11

0.35

> 300

10

6249

Fixed

1.99(1.78,2.24)

P < 0.00001

0

0.85

Cut-off value

       

≤ 3

7

4518

Fixed

2.06(1.80,2.35)

P < 0.00001

10

0.35

> 3

9

2817

Fixed

1.99(1.69,2.34)

P < 0.00001

0

0.85

Study design

       

Prospective

6

3234

Fixed

2.20(1.89,2.571

P < 0.00001

0

0.43

Retrospective

10

4101

Fixed

1.90(1.65,2.18)

P < 0.00001

0

0.91

Data sources

       

Single

10

3438

Fixed

2.05(1.76,2.38)

P < 0.00001

0

0.49

Multiple

6

3897

Fixed

2.01(1.75,2.32)

P < 0.00001

0

0.78

Cancer type

       

CRC

3

2446

Fixed

2.24(1.84,2.72)

P < 0.00001

0

0.81

GC

7

3392

Fixed

2.01(1.68,2.41)

P < 0.00001

0

0.86

EC

2

326

Fixed

2.79(1.89,4.12)

P < 0.00001

36

0.21

CRLM

1

183

-

1.67(1.06,2.61)

P = 0.03

-

-

HCC

1

384

-

1.70(1.21,2.39)

P = 0.002

-

-

CCA

1

143

-

2.07(1.11,3.86)

P = 0.02

-

-

PC

1

461

-

1.77(1.36,2.31)

P < 0.0001

-

-

DFS

       

Total

6

1651

Fixed

1.82(1.46,2.27)

P < 0.00001

0

0.62

Sample size

       

≤ 300

4

647

Fixed

1.76(1.35,2.30)

P < 0.0001

1

0.39

> 300

2

1004

Fixed

1.95(1.32,2.88)

P < 0.0008

0

0.61

Cut-off value

       

≤ 3

2

724

Fixed

2.06(1.80,2.35)

P < 0.0001

10

0.35

> 3

4

927

Fixed

1.95(1.32,2.88)

P < 0.0008

0

0.61

Study design

       

Prospective

2

572

Fixed

2.20(1.89,2.571

P < 0.00001

0

0.43

Retrospective

4

1079

Fixed

1.90(1.65,2.18)

P < 0.00001

0

0.91

Cancer type

       

CRC

1

578

-

2.16(1.25,3.73)

P = 0.006

-

-

GC

2

601

Fixed

1.89(1.20,2.97)

P = 0.006

0

0.66

EC

1

146

-

2.35(1.28,4.31)

P = 0.006

-

-

CRLM

1

183

-

1.39(0.95,2.03)

P = 0.09

-

-

CCA

1

143

-

2.13(1.15,3.95)

P = 0.02

-

-

RFS

       

Total

7

3177

Fixed

1.53(1.33,1.75)

P < 0.00001

0

0.48

Sample size

       

≤ 300

2

439

Fixed

1.95(1.43,2.67)

P < 0.0001

0

0.61

> 300

5

2738

Fixed

1.44(1.24,1.68)

P < 0.00001

0

0.67

Cut-off value

       

≤ 3

2

1287

Fixed

1.38(1.10,1.73)

P = 0.005

38

0.20

> 3

5

1890

Fixed

1.61(1.36,1.91)

P < 0.00001

0

0.60

Study design

       

Prospective

2

718

Fixed

1.73(1.24,2.42)

P = 0.001

0

0.88

Retrospective

5

2459

Fixed

1.49(1.29,1.72)

P < 0.00001

18

0.30

Data sources

       

Single

4

1787

Fixed

1.46(1.22,1.74)

P < 0.0001

0

0.55

Multiple

3

1390

Fixed

1.63(1.32,2.00)

P < 0.0001

29

0.24

Cancer type

       

CRC

1

608

-

1.56(1.05,2.31)

P = 0.03

-

-

GC

3

1544

Fixed

1.77(1.34,2.35)

P < 0.0001

0

0.96

EC

1

180

-

2.09(1.38,3.16)

P = 0.0005

-

-

HCC

1

384

-

1.41(1.08,1.84)

P = 0.01

-

-

PC

1

461

-

1.29(1.01,1.65)

P = 0.04

-

-

  1. Abbreviations: HR, hazard ratio; CI, confidence interval; I², heterogeneity index (percentage of total variation across studies due to heterogeneity); Ph, P-value for heterogeneity; OS, overall survival; DFS, disease-free survival; RFS, recurrence-free survival; CSS, cancer-specific survival; GC, gastric cancer; EC, esophageal cancer; CRLM, colorectal liver metastasis; CCA, cholangiocarcinoma; PC, pancreatic cancer; HCC, hepatocellular carcinoma
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us